Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2018, Vol. 9 Issue (6) : 1134-1152     DOI: 10.14336/AD.2018.0201
Review |
Molecular Bases of Alzheimer’s Disease and Neurodegeneration: The Role of Neuroglia
Luca Antonina1, Calandra Carmela1, Luca Maria2,*
1Department of Medical and Surgical Sciences and Advanced Technologies “G.F. Ingrassia”, University Hospital Policlinico-Vittorio Emanuele, Catania, 95100 Sicily, Italy
2Department of General Surgery and Medical-Surgical Specialties, Dermatology Clinic, University Hospital Policlinico-Vittorio Emanuele, Catania, 95100 Sicily, Italy
Download: PDF(530 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    

Neuroglia is an umbrella term indicating different cellular types that play a pivotal role in the brain, being involved in its development and functional homeostasis. Glial cells are becoming the focus of recent researches pertaining the pathogenesis of neurodegenerative disorders, Alzheimer’s Disease (AD) in particular. In fact, activated microglia is the main determinant of neuroinflammation, contributing to neurodegeneration. In addition, the oxidative insult occurring during pathological brain aging can activate glial cells that, in turn, can favor the production of free radicals. Moreover, the recent Glycogen Synthase Kinase 3 (GSK-3) hypothesis of AD suggests that GSK3, involved in the regulation of glial cells functioning, could exert a role in amyloid deposition and tau hyper-phosphorylation. In this review, we briefly describe the main physiological functions of the glial cells and discuss the link between neuroglia and the most studied molecular bases of AD. In addition, we dedicate a section to the glial changes occurring in AD, with particular attention to their role in terms of neurodegeneration. In the light of the literature data, neuroglia could play a fundamental role in AD pathogenesis and progression. Further studies are needed to shed light on this topic.

Keywords neuroglia      Alzheimer’s Disease      neurodegeneration      oxidative stress      neuroinflammation      glycogen synthase kinase 3     
Corresponding Authors: Luca Maria   
About author:

Current address: Department of Orthopaedic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.

Issue Date: 26 November 2017
E-mail this article
E-mail Alert
Articles by authors
Luca Antonina
Calandra Carmela
Luca Maria
Cite this article:   
Luca Antonina,Calandra Carmela,Luca Maria. Molecular Bases of Alzheimer’s Disease and Neurodegeneration: The Role of Neuroglia[J]. Aging and disease, 2018, 9(6): 1134-1152.
URL:     OR
Figure 1.  GSK3, a protein ubiquitously expressed in the brain. Some of the targets and inhibitors of GSK-3, as well as some fundamental brain processes regulated by this kinase. GSK-3: glycogen synthase kinase-3; NF-kB: nuclear factor KB; CREB: cAMP; NFAT: nuclear factor of activated T cells; APP: amyloid precursor protein.
Figure 2.  Glial cells in normal and pathological brain aging. The figure summarizes the main glial changes occurring in normal versus pathological brain aging. CP: choroid plexus
[1] Virchow R. Die Cellularpathologie in ihrer Begründung auf physiologische and pathologische Gewebelehre. Berlin: August Hirschwald; 1858.
[2] Jessen KR (2004). Glial cells. Int J Biochem Cell Biol, 36:1861–7.
[3] Soreq L, UK Brain Expression Consortium, North American Brain Expression Consortium, Rose J, Soreq E, Hardy J, et al (2017). Major shifts in glial regional identity are a transcriptional hallmark of human brain aging. Cell Rep, 18:557–70.
[4] Chen WW, Zhang X, Huang WJ (2016). Role of neuroinflammation in neurodegenerative diseases (Review). Mol Med Rep, 13:3391–96.
[5] Andersen JK (2004). Oxidative stress in neurodegeneration: cause or consequence? Nat Med, 10: S18–S25.
[6] Azim K, Butt AM (2011). GSK3β negatively regulates oligodendrocyte differentiation and myelination in vivo. Glia, 59:540–53.
[7] Wang MJ, Huang HY, Chen WF, Chang HF, Kuo JS (2010). Glycogen synthase kinase-3β inactivation inhibits tumor necrosis factor-α production in microglia by modulating nuclear factor κB and MLK3/JNK signaling cascades. J Neuroinflammation, 7: 99.
[8] Hooper C, Killick R, Lovestone S (2008). The GSK3 hypothesis of Alzheimer’s Disease. J Neurochem, 104:1433–39.
[9] Saijo K, Glass CK (2011). Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol, 11:775–87.
[10] Bonfanti L, Peretto P (2007). Radial glial origin of the adult neural stem cells in the subventricular zone. Prog Neurobiol, 83:24–36.
[11] Khakh BS, Sofroniew MV (2015). Diversity of astrocyte functions and phenotypes in neural circuits. Nat Neurosci, 18:942–52.
[12] Liddelow SA, Barres BA (2017). Reactive astrocytes: production, function, and therapeutic potential. Immunity, 46:957–67.
[13] Parpura V, Heneka MT, Montana V, Oliet SHR, Schousboe A, Haydon PG, et al (2012). Glial cells in (patho)physiology. J Neurochem, 121:4–27.
[14] Perea G, Navarrete M, Araque A (2009). Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci, 32:421–31.
[15] Araque A, Perea G (2004). Glial modulation of synaptic transmission in culture. Glia, 47:241–8.
[16] Vesce S, Bezzi P, Volterra A (1999). The highly integrated dialogue between neurons and astrocytes in brain function. Sci Progr, 82:251–70.
[17] Abbott NJ, Rönnbäck L, Hansson E (2006). Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci, 7:41–53.
[18] Attwell D, Buchan AM, Charpak S, Lauritzen M, MacVicar BA, Newman EA (2010). Glial and neuronal control of brain blood flow. Nature, 468:232–43.
[19] Zonta M, Angulo MC, Gobbo S, Rosengarten B, Hossmann KA, Pozzan T, et al (2002). Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. Nat Neurosci, 6:43–50.
[20] Bélanger M, Allaman I, Magistretti PJ (2011). Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab, 14:724–38.
[21] Genc S, Kurnaz IA, Ozilgen M (2011). Astrocyte-neuron lactate shuttle may boost more ATP supply to the neuron under hypoxic conditions-in silico study supported by in vitro expression data. BMC Syst Biol, 5:162.
[22] Kirkley KS, Popichak KA, Afzali MF, Legare ME, Tjalkens RB (2017). Microglia amplify inflammatory activation of astrocytes in manganese neurotoxicity. J Neuroinflammation, 14:99.
[23] Dong Y, Benveniste EN (2001). Immune function of astrocytes. Glia, 36: 180–90.
[24] Fulmer CG, VonDran MW, Stillman AA, Huang Y, Hempstead BL, Dreyfus CF (2014). Astrocyte-derived BDNF supports myelin protein synthesis after cuprizone-induced demyelination. J Neurosci, 34:8186–96.
[25] Bradl M, Lassmann H (2010). Oligodendrocytes: biology and pathology. Acta Neuropathol, 119:37–53.
[26] Kassmann CM, Nave KA (2008). Oligodendroglial impact on axonal function and survival-a hypothesis. Curr Opin Neurol, 21:235–241.
[27] Butt AM (2006). Neurotransmitter-mediated calcium signalling in oligodendrocyte physiology and pathology. Glia, 54:666–75.
[28] Frühbeis C, Fröhlich D, Kuo WP, Amphornrat J, Thilemann S, Saab AS, et al (2013). Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte-neuron communication. PLoS Biol, 11: e1001604.
[29] Fitzner D, Schnaars M, van Rossum D, Krishnamoorthy G, Dibaj P, Bakhti M, et al (2011). Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis. J Cell Sci, 124:447–58.
[30] Traka M, Podojil JR, McCarthy DP, Miller SD, Popko B (2016). Oligodendrocyte death results in immune-mediated CNS demyelination. Nat Neurosci, 19:65–74.
[31] Peferoen L, Kipp M, Valk P, Noort JM, Amor S (2014). Oligodendrocyte-microglia cross-talk in the central nervous system. Immunology, 141:302–13.
[32] Dai X, Lercher LD, Clinton PM, Du Y, Livingston DL, Vieira C, et al (2003). The trophic role of oligodendrocytes in the basal forebrain. J Neurosci, 23:5846–53.
[33] Silva-Alvarez C, Carrasco M, Balmaceda-Aguilera C, Pastor P, de los Angeles García M, Reinicke K, et al (2005). Ependymal cell differentiation and GLUT1 expression is a synchronous process in the ventricular wall. Neurochem Res, 30:1227–36.
[34] Louvi A, Grove EA (2011). Cilia in the CNS: the quiet organelle claims center stage. Neuron, 69:1046–60.
[35] Mirzadeh Z, Kusne Y, Duran-Moreno M, Cabrales E, Gil-Perotin S, Christian Ortiz C, et al (2017). Bi- and uniciliated ependymal cells define continuous floor-plate-derived tanycytic territories. Nat Commun, 8:13759.
[36] Jiménez AJ, Domínguez-Pinos MD, Guerra MM, Fernández-Llebrez P, Pérez-Fígares JM (2014). Structure and function of the ependymal barrier and diseases associated with ependyma disruption. Tissue Barriers, 2: e28426.
[37] Svanidze IK, Didimova EV, Gvinadze NN (2012). Changes in the activity of the ciliary apparatus of ependymal cells in the midbrain cerebral aqueduct induced by a number of cerebrospinal fluid neurotransmitters. Neurosci Behav Physiol, 42:72–4.
[38] Alvarez JI, Teale JM (2007). Differential changes in junctional complex proteins suggest the ependymal lining as the main source of leukocyte infiltration into ventricles in murine neurocysticercosis. J Neuroimmunol, 187: 102–13.
[39] Genzen JR, Platel JC, Rubio ME, Bordey A (2009). Ependymal cells along the lateral ventricle express functional P2X7 receptors. Purinergic Signal, 5: 299–307.
[40] Béjot Y, Prigent-Tessier A, Cachia C, Giroud M, Mossiat C, Bertrand N, et al (2011). Time-dependent contribution of non-neuronal cells to BDNF production after ischemic stroke in rats. Neurochem Int, 58:102–11.
[41] Spassky N, Merkle FT, Flames N, Tramontin AD, García-Verdugo JM, Alvarez-Buylla A (2005). Adult ependymal cells are postmitotic and are derived from radial glial cells during embryogenesis. J Neurosci, 25:10–18.
[42] Malatesta P, Appolloni I, Calzolari F. Radial glia and neural stem cells (2008). Cell Tissue Res, 331:165–78.
[43] Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD (2000). NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci, 20:6404–12.
[44] Tramontin AD, García-Verdugo JM, Lim DA, Alvarez-Buylla A (2003). Postnatal development of radial glia and the ventricular zone (VZ): a continuum of the neural stem cell compartment. Cereb Cortex, 13:580–7.
[45] Anthony TE, Klein C, Fishell G, Heintz N (2004). Radial glia serve as neuronal progenitors in all regions of the central nervous system. Neuron, 41:881–90.
[46] Parnavelas JG, Nadarajah B (2001). Radial glial cells: are they really glia? Neuron, 31:881–4.
[47] Shen Q, Wang Y, Kokovay E, Lin G, Chuang SM, Goderie SK, et al (2008). Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of niche cell-cell interactions. Cell Stem Cell, 3:289–300.
[48] Mori T, Buffo A, Götz M (2005). The novel roles of glial cells revisited: the contribution of radial glia and astrocytes to neurogenesis. Curr Top Dev Biol, 69:67–99.
[49] Malatesta P, Hack MA, Hartfuss E, Kettenmann H, Klinkert W, Kirchhoff F, et al (2003). Neuronal or glial progeny: regional differences in radial glia fate. Neuron, 37:751–64.
[50] Gotz M, Barde YA (2005). Radial glial cells defined and major intermediates between embryonic stem cells and CNS neurons. Neuron, 46:369–72.
[51] Cao X, Li LP, Qin XH, Li SJ, Zhang M, Wang Q, et al (2013). Astrocytic adenosine 5'-triphosphate release regulates the proliferation of neural stem cells in the adult hippocampus. Stem Cells, 31:1633–43.
[52] Belachew S, Chittajallu R, Aguirre AA, Yuan X, Kirby M, Anderson S, et al (2003). Postnatal NG2 proteoglycan-expressing progenitor cells are intrinsically multipotent and generate functional neurons. J Cell Biol, 161: 169–86.
[53] Nishiyama A, Komitova M, Suzuki R, Zhu X (2009). Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity. Nat Rev Neurosci, 10:9–22.
[54] Dawson MR, Levine JM, Reynolds R (2000). NG2-expressing cells in the central nervous system: are they oligodendroglial progenitors? J Neurosci Res, 61:471–9.
[55] Zhu X, Bergles DE, Nishiyama A (2008). NG2 cells generate both oligodendrocytes and gray matter astrocytes. Development, 135:145–57.
[56] Richardson WD, Young KM, Tripathi RB, McKenzie I (2011). NG2-glia as multipotent neural stem cells: fact or fantasy? Neuron, 70:661–73.
[57] Aguirre AA, Chittajallu R, Belachew S, Gallo V (2004). NG2-expressing cells in the subventricular zone are type C-like cells and contribute to interneuron generation in the postnatal hippocampus. J Cell Biol, 165: 575–89.
[58] Färber K, Kettenmann H (2005). Physiology of microglial cells. Brain Res Rev, 48:133–43.
[59] Bilimoria PM, Stevens B (2015). Microglia function during brain development: New insights from animal models. Brain Res, 1617:7–17.
[60] Kettenmann H, Kirchhoff F, Verkhratsky A (2013). Microglia: new roles for the synaptic stripper. Neuron, 77:10–8.
[61] Reemst K, Noctor SC, Lucassen PJ, Hol EM (2016). The indispensable roles of microglia and astrocytes during brain development. Front Hum Neurosci, 10: 566.
[62] Fetler L, Amigorena S (2005). Brain under surveillance: the microglia patrol. Science, 309:392–3.
[63] Kawabori M, Yenari MA (2015). The role of the microglia in acute CNS injury. Metab Brain Dis, 30:381–92.
[64] Olson JK, Miller SD (2004). Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol, 173:3916–24.
[65] Aloisi F (2001). Immune function of microglia. Glia, 36:165–79.
[66] Pocock JM, Kettenmann H (2007). Neurotransmitter receptors on microglia. Trends Neurosci, 30:527–35.
[67] Streit WJ, Mrak RE, Griffin WS (2004). Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation, 1:14.
[68] DeLegge MH, Smoke A (2008). Neurodegeneration and inflammation. Nutr Clin Pract, 23:35–41.
[69] Burns A, Iliffe S (2009). Alzheimer's disease. BMJ, 338: b158.
[70] Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G (2013). Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol, 9:106–18.
[71] Shadfar S, Hwang CJ, Lim MS, Choi DY, Hong JT (2015). Involvement of inflammation in Alzheimer's disease pathogenesis and therapeutic potential of anti-inflammatory agents. Arch Pharm Res, 38:2106–19.
[72] Hardy J (2006). A hundred years of Alzheimer's disease research. Neuron, 52:3–13.
[73] Reitz C, Mayeux R (2014). Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol, 88:640–51.
[74] Lassmann H, Bancher C, Breitschopf H, Wegiel J, Bobinski M, Jellinger K, et al (1995). Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol, 89:35–41.
[75] Hardy J, Selkoe DJ (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297:353–6.
[76] Luca M, Luca A, Calandra C (2013). Accelerated aging in major depression: the role of nitro-oxidative stress. Oxid Med Cell Longev, 2013:230797.
[77] Mariani E, Polidori MC, Cherubini A, Mecocci P (2005). Oxidative stress in brain aging, neurodegenerative and vascular diseases: An overview. J Chromatogr B Analyt Technol Biomed Life Sci, 827:65–75.
[78] Luca M, Luca A, Calandra C (2015). The role of oxidative damage in the pathogenesis and progression of Alzheimer’s disease and vascular dementia. Oxid Med Cell Longev, 2015:504678.
[79] Newton DF, Naiberg MR, Goldstein BI (2015). Oxidative stress and cognition amongst adults without dementia or stroke: implications for mechanistic and therapeutic research in psychiatric disorders. Psychiatry Res, 227:127–34.
[80] Yehuda S, Rabinovitz S, Carasso RL, Mostofsky DI (2002). The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiol Aging, 23:843–53.
[81] Passos JF, von Zglinicki T, Saretzki G (2006). Mitochondrial dysfunction and cell senescence: cause or consequence? Rejuvenation Res, 9:64–8.
[82] Christen Y (2000). Oxidative stress and Alzheimer disease. Am J Clin Nutr, 71:621S–29S.
[83] Schrag M, Mueller C, Zabel M, Crofton A, Kirsch WM, Ghribi O, et al (2013). Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: a meta-analysis. Neurobiol Dis, 59:100–10.
[84] Baloyannis SJ (2006). Mitochondrial alterations in Alzheimer's disease. J Alzheimers Dis, 9:119–26.
[85] Sastre M, Ritchie CW, Hajji N (2015). Metal ions in Alzheimer’s disease brain. JSM Alzheimers Dis Relat Dement, 2:1014.
[86] Hara H, Aizenman E (2014). Oxidative stress and neuronal zin signaling. In: Fukada T Kambe T, editors. Zinc Signals in Cellular Functions and Disorders. Tokyo: Springer, 55–87.
[87] Liu L, Komatsu H, Murray IVJ, Axelsen PH (2008). Promotion of amyloid β protein misfolding and fibrillogenesis by a lipid oxidation product. J Mol Biol, 377:1236–50.
[88] Atwood CS, Robinson SR, Smith MA (2002). Amyloid-beta: redox-metal chelator and antioxidant. J Alzheimers Dis, 4:203–14.
[89] Melov S, Adlard PA, Morten K, Johnson F, Golden TR, Hinerfeld D, et al (2007). Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS ONE, 2: e536.
[90] Dias-Santagata D, Fulga TA, Duttaroy A, Feany MB (2007). Oxidative stress mediates tau-induced neurodegeneration in Drosophila. J Clin Invest, 117:236–45.
[91] Simpson JE, Ince PG, Haynes LJ, Theaker R, Gelsthorpe C, Baxter L, et al (2010). Population variation in oxidative stress and astrocyte DNA damage in relation to Alzheimer-type pathology in the ageing brain. Neuropathol Appl Neurobiol, 36:25–40.
[92] Myung NH, Zhu X, Kruman II, Castellani RJ, Petersen RB, Siedlak SL, et al (2008). Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes. Age (Dordr), 30:209–15.
[93] Cai Z, Xiao M (2016). Oligodendrocytes and Alzheimer's disease. Int J Neurosci, 126:97–104.
[94] van Assema DM, Lubberink M, Bauer M, van der Flier WM, Schuit RC, Windhorst AD, et al (2012). Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain, 135:181–89.
[95] Felix RA, Barrand MA (2002). P-glycoprotein expression in rat brain endothelial cells: evidence for regulation by transient oxidative stress. J Neurochem, 80:64–72.
[96] Erickson MA, Hansen K, Banks WA (2012). Inflammation-induced dysfunction of the low-density lipoprotein receptor-related protein-1 at the blood-brain barrier: protection by the antioxidant N-acetylcysteine. Brain Behav Immun, 26:1085–94.
[97] Le Belle JE, Orozco NM, Paucar AA, Saxe JP, Mottahedeh J, Pyle AD, et al (2011). Proliferative neural stem cells have high endogenous ROS levels that regulate self-renewal and neurogenesis in a PI3K/Akt-dependant manner. Cell Stem Cell, 8:59–71.
[98] Taupin P (2010). A dual activity of ROS and oxidative stress on adult neurogenesis and Alzheimer's disease. Cent Nerv Syst Agents Med Chem, 10:16–21.
[99] Sun D, Chen J, Bao X, Cai Y, Zhao J, Huang J, et al (2015). Protection of radial glial-like cells in the hippocampus of APP/PS1 mice: a novel mechanism of memantine in the treatment of Alzheimer's disease. Mol Neurobiol, 52:464–77.
[100] Nielsen HM, Ek D, Avdic U, Orbjörn C, Hansson O, The Netherlands Brain Bank, et al (2013). NG2 cells, a new trail for Alzheimer’s disease mechanisms? Acta Neuropathol Commun, 1:7.
[101] Solito E, Sastre M (2012). Microglia function in Alzheimer’s disease. Front Pharmacol, 3:14.
[102] Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG (2009). Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener, 4:47.
[103] Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, et al (1998). Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol, 8:65–72.
[104] Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, et al (2007). Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol, 170:680–92.
[105] Chakrabarty P, Tianbai L, Herring A, Ceballos-Diaz C, Das P, Golde TE (2012). Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol Neurodegener, 7:36.
[106] Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al (2015). Neuroinflammation in Alzheimer's disease. Lancet Neurol, 14:388–405.
[107] Hein AM, O’Banion MK (2009). Neuroinflammation and memory: the role of prostaglandins. Mol Neurobiol, 40:15–32.
[108] Erta M, Quintana A, Hidalgo J (2012). Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci, 8:1254–66.
[109] Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, et al (2010). Massive gliosis induced by interleukin-6 suppresses Aβ deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J, 24:548–59.
[110] Licastro F, Grimaldi LM, Bonafè M, Martina C, Olivieri F, Cavallone L, et al (2003). Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol Aging, 24:921–6.
[111] Lio D, Licastro F, Scola L, Chiappelli M, Grimaldi LM, Crivello A, et al (2003). Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease. Genes Immun, 4:234–8.
[112] D'Anna L, Abu-Rumeileh S, Fabris M, Pistis C, Baldi A, Sanvilli N, et al (2017). Serum interleukin-10 levels correlate with cerebrospinal fluid amyloid beta deposition in Alzheimer disease patients. Neurodegener Dis, 17: 227–34.
[113] Liu JT, Dong MH, Zhang JQ, Bai Y, Kuang F, Chen LW (2015). Microglia and astroglia: the role of neuroinflammation in lead toxicity and neuronal injury in the brain. Neuroimmunol Neuroinflammation, 2:131–7.
[114] von Bernhardi R, Ramirez G (2001). Microglia-astrocyte interaction in Alzheimer's disease: friends or foes for the nervous system? Biol Res, 34:123–8.
[115] Lattke M, Magnutzki A, Walther P, Wirth T, Baumann B (2012). Nuclear factor κB activation impairs ependymal ciliogenesis and links neuroinflammation to hydrocephalus formation. J Neurosci, 32:11511–23.
[116] Das ND, Chai YG (2013). Neuroinflammation on the epigenetics of neural stem cells. In: Bonfanti L, editor. Neural stem cells: new perspectives. INTECH, 381–96.
[117] Gardiner J, Barton D, Overall R, Marc J (2009). Neurotrophic support and oxidative stress: converging effects in the normal and diseased nervous system. Neuroscientist, 15:47–61.
[118] Yuan TF, Gu S, Shan C, Marchado S, Arias-Carrión O (2015). Oxidative stress and adult neurogenesis. Stem Cell Rev, 11:706–9.
[119] Luca A, Calandra C, Luca M (2016). Gsk3 signalling and redox status in bipolar disorder: evidence from lithium efficacy. Oxid Med Cell Longev, 2016:12 pages.
[120] Moon RT, Kohn AD, De Ferrari GV, Kaykas A (2004). WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet, 5:691–701.
[121] Hur EM, Zhou FQ (2010). GSK3 signalling in neural development. Nat Rev Neurosci, 11:539–51.
[122] Phiel CJ, Wilson CA, Lee VM, Klein PS (2003). GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides. Nature, 423:435–9.
[123] L’Episcopo F, Tirolo C, Caniglia S, Testa N, Morale MC, Serapide MF, et al (2014). Targeting Wnt signaling ate the neuroimmune interface for dopaminergic neuroprotection-repair in Parkinson’s disease. J Mol Cell Biol, 6:13–26.
[124] Inestrosa NC, Toledo EM (2008). The role of Wnt signaling in neuronal dysfunction in Alzheimer’s disease. Mol Neurodegener, 3:9.
[125] Takashima A, Murayama M, Murayama O, Kohno T, Honda T, Yasutake K, et al (1998). Presenilin 1 associates with glycogen synthase kinase-3 beta and its substrate tau. Proc Natl Acad Sci USA, 95:9637–41.
[126] Hernández F, Gómez de Barreda E, Fuster-Matanzo A, Lucas JJ, Avila J (2010). GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol, 223:322–5.
[127] Zhao L, Chu CB, Li JF, Yang YT, Niu SQ, Qin W, et al (2013). Glycogen synthase kinase-3 reduces acetylcholine level in striatum via disturbing cellular distribution of choline acetyltransferase in cholinergic interneurons in rats. Neuroscience, 255:203–11.
[128] Yuskaitis CJ, Jope RS (2009). Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal, 21:264–73.
[129] Beurel E, Jope RS (2010). Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes. Neuroscience, 169:1063–70.
[130] Liu L, Wan W, Xia S, Kalionis B, Li Y (2014). Dysfunctional Wnt/β-catenin signaling contributes to blood-brain barrier breakdown in Alzheimer's disease. Neurochem Int, 75:19–25.
[131] Lim JC, Mickute Z, Zaman M, Hopkins S, Wijesuriya H, Steckler T, et al (2009). Decreased expression of multidrug efflux transporters in the brains of GSK-3beta transgenic mice. Brain Res, 1276:1–10.
[132] Lim JC, Kania KD, Wijesuriya H, Chawla S, Sethi JK, Pulaski L, et al (2008). Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem, 106:1855–65.
[133] Holowacz T, Alexson TO, Coles BL, Doble BW, Kelly KF, Woodgett JR, et al (2013). The responses of neural stem cells to the level of GSK-3 depend on the tissue of origin. Biol Open, 2:812–21.
[134] Crews L, Masliah E (2010). Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet, 19: R12–20.
[135] Mattson MP, Chan SL (2003). Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium, 34:385–97.
[136] Orre M, Kamphuis W, Dooves S, Kooijman L, Chan ET, Kirk CJ, et al. (2013). Reactive glia show increased immunoproteasome activity in Alzheimer's disease. Brain, 136:1415–31.
[137] Matute C, Domercq M, Sánchez-Gómez MV (2006). Glutamate-mediated glial injury: mechanisms and clinical importance. Glia, 53:212–24.
[138] Rodríguez JJ, Olabarria M, Chvatal A, Verkhratsky A (2009). Astroglia in dementia and Alzheimer's disease. Cell Death Differ, 16:378–85.
[139] Rodríguez-Arellano JJ, Parpura V, Zorec R, Verkhratsky A (2016). Astrocytes in physiological aging and Alzheimer's disease. Neuroscience, 323:170–82.
[140] Olabarria M, Noristani HN, Verkhratsky A, Rodríguez JJ (2010). Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. Glia, 58:831–8.
[141] Wyssenbach A, Quintela T, Llavero F, Zugaza JL, Matute C, Alberdi E (2016). Amyloid β-induced astrogliosis is mediated by β1-integrin via NADPH oxidase 2 in Alzheimer's disease. Aging Cell, In press
[142] Abramov AY, Canevari L, Duchen MR (2003). Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J Neurosci, 23:5088–95.
[143] Verkhratsky A, Olabarria M, Noristani HN, Yeh CY, Rodriguez JJ (2010). Astrocytes in Alzheimer's disease. Neurotherapeutics, 7:399–412.
[144] Abramov AY, Canevari L, Duchen MR (2004). b-Amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci, 24:565–575.
[145] Kahlson MA, Colodner KJ (2016). Glial tau pathology in tauopathies: functional consequences. J Exp Neurosci, 9:43–50.
[146] Kovacs GG, Lee VM, Trojanowski JQ (2017). Protein astrogliopathies in human neurodegenerative diseases and aging. Brain Pathol, 27:675–690.
[147] Nagele RG, D'Andrea MR, Lee H, Venkataraman V, Wang HY (2003). Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res, 971:197–209.
[148] Bartzokis G (2004). Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging, 25:5–18.
[149] Roth AD, Ramírez G, Alarcón R, Von Bernhardi R (2005). Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation. Biol Res, 38:381–7.
[150] Desai MK, Mastrangelo MA, Ryan DA, Sudol KL, Narrow WC, Bowers WJ (2010). Early oligodendrocyte/myelin pathology in Alzheimer's disease mice constitutes a novel therapeutic target. Am J Pathol, 177:1422–35.
[151] Kobayashi K, Hayashi M, Nakano H, Fukutani Y, Sasaki K, Shimazaki M, et al. (2002). Apoptosis of astrocytes with enhanced lysosomal activity and oligodendrocytes in white matter lesions in Alzheimer's disease. Neuropathol Appl Neurobiol, 28:238–51.
[152] Honjo Y, Ayaki T, Tomiyama T, Horibe T, Ito H, Mori H, et al. (2017). Decreased levels of PDI and P5 in oligodendrocytes in Alzheimer's disease. Neuropathology, In press
[153] Honjo Y, Ayaki T, Tomiyama T, Horibe T, Ito H, Mori H, et al. (2015). Increased GADD34 in oligodendrocytes in Alzheimer's disease. Neurosci Lett, 602: 50–5.
[154] Sjöbeck M, Englund E (2003). Glial levels determine severity of white matter disease in Alzheimer's disease: a neuropathological study of glial changes. Neuropathol Appl Neurobiol, 29:159–69.
[155] Serot JM, Zmudka J, Jouanny P (2012). A possible role for CSF turnover and choroid plexus in the pathogenesis of late onset Alzheimer's disease. J Alzheimers Dis, 30:17–26.
[156] Serot JM, Béné MC, Faure GC (2003). Choroid plexus, aging of the brain, and Alzheimer's disease. Front Biosci, 8: s515–21.
[157] Miklossy J, Kraftsik R, Pillevuit O, Lepori D, Genton C, Bosman FT (1998). Curly fiber and tangle-like inclusions in the ependyma and choroid plexus-a pathogenetic relationship with the cortical Alzheimer-type changes? J Neuropathol Exp Neurol, 57:1202–12.
[158] Moredock KM, Cirrito JR, Holtzman DM and Krane CM (2008). Aquaporin-4 expression is altered around the lateral ventricle in correlation with beta-amyloid plaque expression in a transgenic mouse model of Alzheimer’s Disease. The FASEB Journal, 22:1199–1.
[159] Alvira-Botero X, Carro EM (2010). Clearance of amyloid-β peptide across the choroid plexus in Alzheimer's disease. Curr Aging Sci, 3:219–29.
[160] Maślińska D, Laure-Kamionowska M, Taraszewska A, Deręgowski K, Maśliński S (2011). Immunodistribution of amyloid beta protein (Aβ) and advanced glycation end-product receptors (RAGE) in choroid plexus and ependyma of resuscitated patients. Folia Neuropathol, 49:295–300.
[161] Miller MC, Tavares R, Johanson CE, Hovanesian V, Donahue JE, Gonzalez L, et al. (2008). Hippocampal RAGE immunoreactivity in early and advanced Alzheimer’s disease. Brain Res, 1230: 273–80.
[162] Carro E, Trejo JL, Spuch C, Bohl D, Heard JM, Torres-Aleman I (2006). Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease? Neurobiol Aging, 27:1618–31.
[163] Bolos M, Antequera D, Aldudo J, Kristen H, Bullido MJ, Carro E (2014). Choroid plexus implants rescue Alzheimer's disease-like pathologies by modulating amyloid-β degradation. Cell Mol Life Sci, 71:2947–55.
[164] Bolos M, Spuch C, Ordoñez-Gutierrez L, Wandosell F, Ferrer I, Carro E (2013). Neurogenic effects of β-amyloid in the choroid plexus epithelial cells in Alzheimer's disease. Cell Mol Life Sci, 70:2787–97.
[165] Rusznák Z, Henskens W, Schofield E, Kim WS, Fu Y (2016). Adult neurogenesis and gliogenesis: possible mechanisms for neurorestoration. Exp Neurobiol, 25:103–12.
[166] Kohman RA, Rhodes JS (2013). Neurogenesis, inflammation and behavior. Brain Behav Immun, 27:22–32.
[167] Galvan V, Jin K (2007). Neurogenesis in the aging brain. Clinical Interventions in Aging, 2:605–610.
[168] Baglietto-Vargas D, Sánchez-Mejias E, Navarro V, Jimenez S, Trujillo-Estrada L, Gómez-Arboledas Aet al. (2017). Dual roles of Aβ in proliferative processes in an amyloidogenic model of Alzheimer's disease. Sci Rep, 7:10085.
[169] Gan L, Qiao S, Lan X, Chi L, Luo C, Lien Let al. (2008). Neurogenic responses to amyloid-beta plaques in the brain of Alzheimer's disease-like transgenic (pPDGF-APPSw, Ind) mice. Neurobiol Dis, 29:71–80.
[170] Boekhoorn K, Joels M, Lucassen PJ (2006). Increased proliferation reflects glial and vascular-associated changes, but not neurogenesis in the presenile Alzheimer hippocampus. Neurobiol Dis, 24:1–14.
[171] Rodríguez JJ, Jones VC, Verkhratsky A (2009). Impaired cell proliferation in the subventricular zone in an Alzheimer's disease model. Neuroreport, 20:907–12.
[172] Schinder AF, Morgenstern NA (2009). Preview. Adult neurogenesis is altered by GABAergic imbalance in models of Alzheimer's disease. Cell Stem Cell, 5:573–4.
[173] He P, Shen Y (2009). Interruption of beta-catenin signaling reduces neurogenesis in Alzheimer's disease. J Neurosci, 29:6545–57.
[174] Mazur-Kolecka B, Golabek A, Nowicki K, Flory M, Frackowiak J (2006). Amyloid-beta impairs development of neuronal progenitor cells by oxidative mechanisms. Neurobiol Aging, 27:1181–92.
[175] Zhang C, McNeil E, Dressler L, Siman R (2007). Long-lasting impairment in hippocampal neurogenesis associated with amyloid deposition in a knock-in mouse model of familial Alzheimer's disease. Exp Neurol, 204:77–87.
[176] Waldau B, Shetty AK (2008). Behavior of neural stem cells in the Alzheimer brain. Cell Mol Life Sci, 65:2372–84.
[177] Haughey NJ, Nath A, Chan SL, Borchard AC, Rao MS, Mattson MP (2002). Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J Neurochem, 83:1509–24.
[178] Lee IS, Jung K, Kim IS, Park KI (2013). Amyloid-β oligomers regulate the properties of human neural stem cells through GSK-3β signaling. Exp Mol Med, 45: e60.
[179] Zhou ZD, Chan CH, Ma QH, Xu XH, Xiao ZC, Tan EK (2011). The roles of amyloid precursor protein (APP) in neurogenesis: Implications to pathogenesis and therapy of Alzheimer disease. Cell Adh Migr, 5:280–92.
[180] Yu Y, He J, Zhang Y, Luo H, Zhu S, Yang Yet al. (2009). Increased hippocampal neurogenesis in the progressive stage of Alzheimer's disease phenotype in an APP/PS1 double transgenic mouse model. Hippocampus, 19:1247–53.
[181] Li B, Yamamori H, Tatebayashi Y, Shafit-Zagardo B, Tanimukai H, Chen Set al. (2008). Failure of neuronal maturation in Alzheimer disease dentate gyrus. J Neuropathol Exp Neurol, 67:78–84.
[182] Fuster-Matanzo A, Llorens-Martín M, Jurado-Arjona J, Avila J, Hernández F (2012). Tau protein and adult hippocampal neurogenesis. Front Neurosci, 6:104.
[183] Pallas-Bazarra N, Jurado-Arjona J, Navarrete M, Esteban JA, Hernández F, Ávila J, et al. (2016) Novel function of Tau in regulating the effects of external stimuli on adult hippocampal neurogenesis. EMBO J, 35:1417–36.
[184] Dioli C, Patrício P, Trindade R, Pinto LG, Silva JM, Morais M, et al. (2017). Tau-dependent suppression of adult neurogenesis in the stressed hippocampus. Mol Psychiatry, 22:1110–1118.
[185] Mu Y, Gage FH (2011). Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol Neurodegener, 6:85.
[186] von Bernhardi R (2007). Glial cell dysregulation: a new perspective on Alzheimer disease. Neurotox Res, 12:215–32.
[187] Janelsins MC, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ, Bowers WJ (2005). Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation, 2:23.
[188] Mrak RE (2012). Microglia in Alzheimer brain: a neuropathological perspective. Int J Alzheimers Dis, 2012:165021.
[189] Sarlus H, Heneka MT (2017). Microglia in Alzheimer's disease. J Clin Invest, 127:3240–3249.
[190] Zhang F, Zhong R, Li S, Fu Z, Cheng C, Cai H, et al. (2017). Acute hypoxia induced an imbalanced M1/M2 activation of microglia through NF-κB signaling in Alzheimer's Disease mice and wild-type Littermates. Front Aging Neurosci, 9:282.
[191] Krabbe G, Halle A, Matyash V, Rinnenthal JL, Eom GD, Bernhardt U, et al. (2013). Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One, 8:e 60921.
[192] Neniskyte U, Fricker M, Brown GC (2016). Amyloid β induces microglia to phagocytose neurons via activation of protein kinase Cs and NADPH oxidase. Int J Biochem Cell Biol, 81:346–355.
[193] Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. (2016) Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science, 352:712–716.
[194] Fonseca MI, Chu SH, Hernandez MX, Fang MJ, Modarresi L, Selvan P, et al. (2017) Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain. J Neuroinflammation, 14:48.
[195] Yang LB, Li R, Meri S, Rogers J, Shen Y (2000) Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J Neurosci, 20:7505–7509.
[196] Shi Q, Chowdhury S, Ma R, Le KX, Hong S, Caldarone BJ, et al. (2017) Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Sci Transl Med, 9:392.
[197] Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA (2008). Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci, 28:6333–6341.
[198] Spangenberg EE, Lee RJ, Najafi AR, Rice RA, Elmore MR, Blurton-Jones M, et al. (2016). Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-β pathology. Brain, 139:1265–81.
[199] Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TCet al. (2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron, 53:337–51.
[200] Rodríguez JJ, Witton J, Olabarria M, Noristani HN, Verkhratsky A (2010). Increase in the density of resting microglia precedes neuritic plaque formation and microglial activation in a transgenic model of Alzheimer's disease. Cell Death Dis, 1: e1.
[201] Streit WJ (2006). Microglial senescence: does the brain's immune system have an expiration date? Trends Neurosci, 29:506–10.
[202] Streit WJ, Braak H, Xue QS, Bechmann I (2009). Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol, 118:475–85.
[1] Ren Changhong, Wu Hang, Li Dongjie, Yang Yong, Gao Yuan, Jizhang Yunneng, Liu Dachuan, Ji Xunming, Zhang Xuxiang. Remote Ischemic Conditioning Protects Diabetic Retinopathy in Streptozotocin-induced Diabetic Rats via Anti-Inflammation and Antioxidation[J]. Aging and disease, 2018, 9(6): 1122-1133.
[2] Yong-Fei Zhao, Qiong Zhang, Jian-Feng Zhang, Zhi-Yin Lou, Hen-Bing Zu, Zi-Gao Wang, Wei-Cheng Zeng, Kai Yao, Bao-Guo Xiao. The Synergy of Aging and LPS Exposure in a Mouse Model of Parkinson’s Disease[J]. Aging and disease, 2018, 9(5): 785-797.
[3] Daichi Sone,Etsuko Imabayashi,Norihide Maikusa,Masayo Ogawa,Noriko Sato,Hiroshi Matsuda,Japanese-Alzheimer’s Disease Neuroimaging Initiative. Voxel-based Specific Regional Analysis System for Alzheimer’s Disease (VSRAD) on 3-tesla Normal Database: Diagnostic Accuracy in Two Independent Cohorts with Early Alzheimer’s Disease[J]. A&D, 2018, 9(4): 755-760.
[4] Fabiana Morroni,Giulia Sita,Agnese Graziosi,Eleonora Turrini,Carmela Fimognari,Andrea Tarozzi,Patrizia Hrelia. Neuroprotective Effect of Caffeic Acid Phenethyl Ester in A Mouse Model of Alzheimer’s Disease Involves Nrf2/HO-1 Pathway[J]. A&D, 2018, 9(4): 605-622.
[5] Yangqi Xu, Xiaoli Liu, Junyi Shen, Wotu Tian, Rong Fang, Binyin Li, Jianfang Ma, Li Cao, Shengdi Chen, Guanjun Li, Huidong Tang. The Whole Exome Sequencing Clarifies the Genotype- Phenotype Correlations in Patients with Early-Onset Dementia[J]. Aging and disease, 2018, 9(4): 696-705.
[6] Yali Chen, Mengmei Yin, Xuejin Cao, Gang Hu, Ming Xiao. Pro- and Anti-inflammatory Effects of High Cholesterol Diet on Aged Brain[J]. Aging and disease, 2018, 9(3): 374-390.
[7] Qiong Ding,Kitora Tanigawa,Jun Kaneko,Mamoru Totsuka,Yoshinori Katakura,Etsuko Imabayashi,Hiroshi Matsuda,Tatsuhiro Hisatsune. Anserine/Carnosine Supplementation Preserves Blood Flow in the Prefrontal Brain of Elderly People Carrying APOE e4[J]. A&D, 2018, 9(3): 334-345.
[8] Ting Shen,Yuyi You,Chitra Joseph,Mehdi Mirzaei,Alexander Klistorner,Stuart L. Graham,Vivek Gupta. BDNF Polymorphism: A Review of Its Diagnostic and Clinical Relevance in Neurodegenerative Disorders[J]. A&D, 2018, 9(3): 523-536.
[9] Meng Zhang,Yong-Ning Deng,Jing-Yi Zhang,Jie Liu,Yan-Bo Li,Hua Su,Qiu-Min Qu. SIRT3 Protects Rotenone-induced Injury in SH-SY5Y Cells by Promoting Autophagy through the LKB1-AMPK-mTOR Pathway[J]. A&D, 2018, 9(2): 273-286.
[10] Fangyu Peng,Fang Xie,Otto Muzik. Alteration of Copper Fluxes in Brain Aging: A Longitudinal Study in Rodent Using 64CuCl2-PET/CT[J]. A&D, 2018, 9(1): 109-118.
[11] Jue Wang,Bin Cao,Haiping Zhao,Juan Feng. Emerging Roles of Ganoderma Lucidum in Anti-Aging[J]. A&D, 2017, 8(6): 691-707.
[12] Mari L. Sbardelotto,Giulia S. Pedroso,Fernanda T. Pereira,Helen R. Soratto,Stella MS. Brescianini,Pauline S. Effting,Anand Thirupathi,Renata T. Nesi,Paulo CL. Silveira,Ricardo A. Pinho. The Effects of Physical Training are Varied and Occur in an Exercise Type-Dependent Manner in Elderly Men[J]. A&D, 2017, 8(6): 887-898.
[13] Guofen Gao, Nan Zhang, Yue-Qi Wang, Qiong Wu, Peng Yu, Zhen-Hua Shi, Xiang-Lin Duan, Bao-Lu Zhao, Wen-Shuang Wu, Yan-Zhong Chang. Mitochondrial Ferritin Protects Hydrogen Peroxide-Induced Neuronal Cell Damage[J]. A&D, 2017, 8(4): 458-470.
[14] Anindita Banerjee,Vineet Kumar Khemka,Debashree Roy,Aparajita Dhar,Tapan Kumar Sinha Roy,Atanu Biswas,Barun Mukhopadhyay,Sasanka Chakrabarti. Role of Pro-Inflammatory Cytokines and Vitamin D in Probable Alzheimer's Disease with Depression[J]. A&D, 2017, 8(3): 267-276.
[15] Diana L Castillo-Carranza,Ashley N Nilson,Candice E Van Skike,Jordan B Jahrling,Kishan Patel,Prajesh Garach,Julia E Gerson,Urmi Sengupta,Jose Abisambra,Peter Nelson,Juan Troncoso,Zoltan Ungvari,Veronica Galvan,Rakez Kayed. Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer’s Disease and Related Tauopathies[J]. A&D, 2017, 8(3): 257-266.
Full text



Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail:
Powered by Beijing Magtech Co. Ltd